Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
J Int Med Res ; 23(4): 219-27, 1995.
Article in English | MEDLINE | ID: mdl-7589764

ABSTRACT

The efficacy and safety of two different regimens of dihydroergocristine, in the treatment of patients with chronic cerebro-vascular disease, were compared in this double-blind study. Forty out-patients, 11 males and 29 females, aged 55-80 years were randomly assigned to treatment with 6 or 20 mg dihydroergocristine, daily, for 3 months. The Sandoz Clinical Assessment for Geriatrics (SCAG) scale was used to assess the efficacy of treatment. Both doses induced a statistically significant improvement (P < 0.01) in total SCAG scores after both 45 and 90 days of treatment. The higher dose produced a significantly greater improvement in total SCAG scores than did the lower dose after both 45 and 90 days. There were no statistically or clinically significant changes in any of the laboratory parameters after either treatment; neither were there any statistically significant changes in blood-pressure or pulse-rate except in the case of standing systolic pressure which decreased significantly (P < 0.01) in the 20 mg group. The only adverse event reported was a case of mild gastric pain at the end of treatment with 20 mg dihydroergocristine.


Subject(s)
Cerebrovascular Disorders/drug therapy , Dihydroergotoxine/administration & dosage , Neuroprotective Agents/administration & dosage , Aged , Dihydroergotoxine/therapeutic use , Double-Blind Method , Female , Humans , Male , Middle Aged , Neuroprotective Agents/therapeutic use
2.
Minerva Med ; 72(35): 2367-71, 1981 Sep 22.
Article in Italian | MEDLINE | ID: mdl-7279259

ABSTRACT

Reference is made to a personal case in an account of the clinical and pathological criteria that provide the diagnostic hinges of angio-immunoblastic lymphadenopathy. Stress is laid on the systemic and progressive nature of the disease, and support is given to the view that is an affection of the immuno-competent system. The fact that the course is unpredictable is seen as a reason for adopting an extremely cautions therapeutic approach based on corticosteroid hormones. Resort to the cytotoxic chemotherapeutical drugs customarily employed in other lymphoproliferative forms should be reserved for a few selected cases.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Immunoblastic Lymphadenopathy/drug therapy , Dermatitis/etiology , Female , Humans , Lymph Nodes/pathology , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...